Switch theme
Sign up to access all valuation multiples
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.
1979
389
LTM Revenue $127M
LTM EBITDA $13.8M
$409M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Surmodics has a last 12-month revenue of $127M and a last 12-month EBITDA of $13.8M.
In the most recent fiscal year, Surmodics achieved revenue of $126M and an EBITDA of $4.7M.
Surmodics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Surmodics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $133M | $126M | XXX | XXX | XXX |
| Gross Profit | $29.0M | $61.0M | XXX | XXX | XXX |
| Gross Margin | 22% | 48% | XXX | XXX | XXX |
| EBITDA | $14.5M | $4.7M | XXX | XXX | XXX |
| EBITDA Margin | 11% | 4% | XXX | XXX | XXX |
| Net Profit | -$27.3M | -$1.5M | XXX | XXX | XXX |
| Net Margin | -21% | -1% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Surmodics's stock price is $28.
Surmodics has current market cap of $407M, and EV of $409M.
See Surmodics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $409M | $407M | XXX | XXX | XXX | XXX | $-0.29 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Surmodics has market cap of $407M and EV of $409M.
Surmodics's trades at 3.2x LTM EV/Revenue multiple, and 29.6x LTM EBITDA.
Analysts estimate Surmodics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Surmodics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $409M | XXX | XXX | XXX |
| EV/Revenue | 3.2x | XXX | XXX | XXX |
| EV/EBITDA | 60.1x | XXX | XXX | XXX |
| P/E | -37.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -177.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSurmodics's NTM/LTM revenue growth is 1%
Surmodics's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Surmodics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Surmodics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Surmodics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -5% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 5% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -67% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 6% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 48% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Surmodics acquired XXX companies to date.
Last acquisition by Surmodics was XXXXXXXX, XXXXX XXXXX XXXXXX . Surmodics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Surmodics founded? | Surmodics was founded in 1979. |
| Where is Surmodics headquartered? | Surmodics is headquartered in United States of America. |
| How many employees does Surmodics have? | As of today, Surmodics has 389 employees. |
| Who is the CEO of Surmodics? | Surmodics's CEO is Mr. Gary R. Maharaj. |
| Is Surmodics publicy listed? | Yes, Surmodics is a public company listed on NAS. |
| What is the stock symbol of Surmodics? | Surmodics trades under SRDX ticker. |
| When did Surmodics go public? | Surmodics went public in 1998. |
| Who are competitors of Surmodics? | Similar companies to Surmodics include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Surmodics? | Surmodics's current market cap is $407M |
| What is the current revenue of Surmodics? | Surmodics's last 12-month revenue is $127M. |
| What is the current EBITDA of Surmodics? | Surmodics's last 12-month EBITDA is $13.8M. |
| What is the current EV/Revenue multiple of Surmodics? | Current revenue multiple of Surmodics is 3.2x. |
| What is the current EV/EBITDA multiple of Surmodics? | Current EBITDA multiple of Surmodics is 29.6x. |
| What is the current revenue growth of Surmodics? | Surmodics revenue growth between 2023 and 2024 was -5%. |
| Is Surmodics profitable? | Yes, Surmodics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
